Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication - PubMed (original) (raw)
Clinical Trial
Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication
William M Stone et al. J Stroke Cerebrovasc Dis. 2008 May-Jun.
Abstract
Objective: The risk of cerebrovascular events in patients with mild to moderate peripheral vascular disease is significant. Cilostazol is a phosphodiesterase type 3 (PDE3) inhibitor that is effective in the treatment of symptoms of peripheral arterial occlusive disease. The method of action includes antithrombotic, vasodilatory, and antiproliferative effects.
Methods: The Cilostazol: A Study in Long-Term Effects (CASTLE) trial was a prospective randomized double-blinded trial to establish the safety of this PDE3 inhibitor use in 1435 patients with mild to moderate peripheral arterial occlusive disease. A post hoc analysis of the CASTLE trial was undertaken to evaluate cilostazol use on cerebrovascular events. Blinded adjudication of all cerebrovascular events (stroke, transient ischemic attack, and carotid revascularization) in this trial was performed. Kaplan-Meier analysis was used for statistical evaluation.
Results: The overall rate of cerebrovascular events was 4.6% (67 of 1435 patients) with a mean follow-up of 515 days. Ischemic vascular events were more common (2.5%) than hemorrhagic events (0.3%; P < .05). The placebo group demonstrated a greater risk for events (6.1%; 43 of 718 patients) versus the cilostazol treated group (3.2%; 24 of 717 patients; P < .05). Cerebrovascular risk factors were similar in both groups.
Conclusion: The risk of cerebrovascular events in patients with mild to moderate peripheral arterial occlusive disease is 4.6% with a mean follow-up of 515 days. Treatment with PDE3 inhibitors may reduce this risk. Further evaluation of the use of PDE3 inhibitors for prevention of cerebrovascular events should be considered.
Similar articles
- Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Hiatt WR, Money SR, Brass EP. Hiatt WR, et al. J Vasc Surg. 2008 Feb;47(2):330-336. doi: 10.1016/j.jvs.2007.10.009. Epub 2007 Dec 26. J Vasc Surg. 2008. PMID: 18155871 Clinical Trial. - Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
Samra SS, Bajaj P, Vijayaraghavan KS, Potdar NP, Vyas D, Devani RG, Ballary C, Desai A. Samra SS, et al. J Indian Med Assoc. 2003 Sep;101(9):561-2, 564. J Indian Med Assoc. 2003. PMID: 15168999 Clinical Trial. - Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Shigematsu H, Nishibe T, Obitsu Y, Matsuzaki K, Ishida A, Miyata T, Shindo S, Hida K, Ohta T, Ando M, Kawasaki T, Yasugi T, Matsumoto T. Shigematsu H, et al. Int Angiol. 2010 Apr;29(2 Suppl):2-13. Int Angiol. 2010. PMID: 20357743 - Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Liu Y, et al. Cardiovasc Drug Rev. 2001 Winter;19(4):369-86. doi: 10.1111/j.1527-3466.2001.tb00076.x. Cardiovasc Drug Rev. 2001. PMID: 11830753 Review. - Cilostazol: improving walking distance in patients with intermittent claudication.
Collinson DJ, Donnelly R. Collinson DJ, et al. Expert Rev Cardiovasc Ther. 2004 Jul;2(4):503-9. doi: 10.1586/14779072.2.4.503. Expert Rev Cardiovasc Ther. 2004. PMID: 15225110 Review.
Cited by
- Cilostazol for intermittent claudication.
Brown T, Forster RB, Cleanthis M, Mikhailidis DP, Stansby G, Stewart M. Brown T, et al. Cochrane Database Syst Rev. 2021 Jun 30;6(6):CD003748. doi: 10.1002/14651858.CD003748.pub5. Cochrane Database Syst Rev. 2021. PMID: 34192807 Free PMC article. - Cilostazol Inhibits Vascular Smooth Muscle Cell Proliferation and Reactive Oxygen Species Production through Activation of AMP-activated Protein Kinase Induced by Heme Oxygenase-1.
Kim JE, Sung JY, Woo CH, Kang YJ, Lee KY, Kim HS, Kwun WH, Choi HC. Kim JE, et al. Korean J Physiol Pharmacol. 2011 Aug;15(4):203-10. doi: 10.4196/kjpp.2011.15.4.203. Epub 2011 Aug 31. Korean J Physiol Pharmacol. 2011. PMID: 21994478 Free PMC article. - Coronary Vasospastic Angina: A Review of the Pathogenesis, Diagnosis, and Management.
Rehan R, Weaver J, Yong A. Rehan R, et al. Life (Basel). 2022 Jul 27;12(8):1124. doi: 10.3390/life12081124. Life (Basel). 2022. PMID: 36013303 Free PMC article. Review. - Cilostazol for intermittent claudication.
Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Bedenis R, et al. Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD003748. doi: 10.1002/14651858.CD003748.pub4. Cochrane Database Syst Rev. 2014. PMID: 25358850 Free PMC article. Updated. Review. - Regulation of cAMP by phosphodiesterases in erythrocytes.
Adderley SP, Sprague RS, Stephenson AH, Hanson MS. Adderley SP, et al. Pharmacol Rep. 2010 May-Jun;62(3):475-82. doi: 10.1016/s1734-1140(10)70303-0. Pharmacol Rep. 2010. PMID: 20631411 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources